Surgery: there are radical esophageal cancer surgery with right thoracic approach with three-field lymph node dissection in lower neck and chest and abdomen, and radical esophageal cancer surgery with right (left) thoracic approach with two-field lymph node dissection in chest and abdomen. Most experts think that radical esophageal cancer surgery with three-field lymph node dissection has thorough lymph node dissection, and has good prognosis, but it is a very traumatic surgery, and for the lower and mid-thoracic esophageal cancers that do not have lymph node metastasis by ultrasound examination of neck, survival rate has not been improved. At present, it is believed that minimally invasive modified three-field lymph node dissection radical esophageal cancer surgery, with the number of lymph nodes cleared more than 15, has the best effect. 2. Radiotherapy methods: there are conventional radiotherapy, conformal radiotherapy and intensity-modulated conformal radiotherapy. At present, the best one is intensity-modulated conformal radiotherapy, which not only makes the shape of the irradiation field consistent with the shape of the target area in irradiation direction, but also adjusts to increase the dose of the target area of the tumor, reduce the dose of the endangered organs, and better protect the normal tissues, so that the local control rate of the tumor and the survival rate can be improved obviously, and the adverse reaction of radiotherapy is light. Selection of first-line chemotherapy regimen: commonly used are DDP (cisplatin) + 5-FU (5-fluorouracil), DDP + CF (calcium folinate) + 5-FU, DDP or NDP (nedaplatin) + PTX (paclitaxel) or TXT (docetaxel), etc. The chemotherapy regimen of paclitaxel plus cisplatin for the treatment of esophageal cancer has already replaced the traditional 5-fluorouracil plus cisplatin chemotherapy regimen due to the high effectiveness rate and mild mucous membrane reaction in the digestive tract. Fluorouracil plus cisplatin has replaced the traditional 5-fluorouracil plus cisplatin chemotherapy program as the first-line chemotherapy program for middle and advanced esophageal cancer. However, due to the high nephrotoxicity and gastrointestinal reaction of cisplatin, hydration is required, and the quality of life of patients is poorer, while nedaplatin is a new generation of platinum drugs, with mild toxic side effects, and no hydration is required. The author’s study found that paclitaxel plus nedaplatin chemotherapy regimen for esophageal cancer has better efficacy than other regimens, and the toxic side effects are mild.